An independent two-stage DCF analysis by a frontier AI model.
Bristol Myers Squibb is the textbook definition of a large-cap pharmaceutical company navigating a terrifying 'patent cliff.' The impending loss of exclusivity for Eliquis, combined with ongoing generic erosion for Revlimid, creates a massive revenue hole that the market fears the company cannot fill. This has resulted in severe multiple compression, with the stock trading at depressed levels relative to its historical averages and its peers.
However, the market is severely undervaluing the massive cash flow BMY is currently generating ($7B+ income, massive FCF) and its aggressive, multi-pronged approach to replacing lost revenue. The 'new product portfolio' is ramping up, and recent multi-billion dollar acquisitions have injected late-stage, high-potential assets into the pipeline. Our DCF model assumes a multi-year period of declining cash flows, yet still finds the stock significantly undervalued. At current prices, BMY offers a substantial margin of safety, compensating investors with a high dividend yield while they wait for the pipeline turnaround to materialize.
A negative 2.0% free cash flow growth rate is modeled for the next five years to account for the peak revenue erosion from the Revlimid and Eliquis patent cliffs, before the new product portfolio fully bridges the gap.
An 8.5% discount rate reflects the elevated risk during this critical pipeline transition period, balanced against the company's historically strong cash flow generation and defensive healthcare sector positioning.
A highly conservative 1.0% terminal growth rate assumes that post-transition, the company stabilizes and grows slightly below the rate of long-term inflation, acknowledging the perpetual challenge of replacing blockbuster drugs.
Intrinsic value per share under varying discount rate and terminal growth rate assumptions.
| WACC ↓ / Terminal → | 0.0% | 0.5% | 1.0% | 1.5% | 2.0% |
|---|---|---|---|---|---|
| 0.0% | $90.52 | $78.45 | $69.22 | $61.93 | $56.04 |
| 0.5% | $98.06 | $84.05 | $73.55 | $65.38 | $58.84 |
| 1.0% | $106.98 | $90.52 | $78.45 | $69.22 | $61.93 |
| 1.5% | $117.68 | $98.06 | $84.05 | $73.55 | $65.38 |
| 2.0% | $130.75 | $106.98 | $90.52 | $78.45 | $69.22 |
■ Undervalued vs current price ■ Overvalued vs current price
Bristol Myers Squibb is a complex deep-value story navigating a perilous transition period. While it boasts a formidable revenue base of over $48 billion and high-margin oncology and immunology franchises, it is confronting major patent cliffs for crucial blockbuster drugs, notably Eliquis and Revlimid. Consequently, competitive momentum is weak, and recent EPS declines highlight the immediate earnings pressure. However, its immense cash flow generation, deep IP portfolio, and aggressive pipeline development (organically and via acquisitions) provide a durable economic moat, keeping it afloat as a moderate prospect during this high-risk transition.
BMY's competitive momentum is currently constrained by the impending loss of exclusivity (LOE) on key growth drivers. While its new product portfolio is growing rapidly, it is struggling to entirely offset the revenue erosion from its legacy blockbusters.
Despite the severe momentum challenges, BMY maintains a robust, durable moat. The pharmaceutical industry's massive capital requirements, long development cycles, and stringent intellectual property protections provide significant long-term structural advantages.
Market sentiment toward BMY is deeply negative, viewing the stock as a 'value trap' until the company can definitively prove its new product portfolio can outgrow the revenue destruction from its aging blockbusters.
BMY is actively losing patent protection on drugs that account for billions in high-margin revenue (Revlimid, Eliquis). Modeling a negative growth rate conservatively accounts for the likely near-term drop in free cash flow before new drugs can scale up to replace them.
Valuation is relative to price. Even with declining cash flows over the next five years, BMY's starting baseline of cash generation is so massive that the discounted sum of those future cash flows still exceeds its current depressed market capitalization.
Yes, implicitly. The model uses the current, depressed free cash flow starting point (which reflects the high debt service and integration costs of recent M&A) and assumes those acquired assets will eventually stabilize the long-term terminal growth rate at 1%.
Disclaimer: The numbers presented on this page are for educational and entertainment purposes only. They are the result of a deterministic mathematical model fed with assumptions generated by an Artificial Intelligence (Gemini 3.1). This does not constitute investment advice. Always conduct your own due diligence before investing in the stock market.